AI English summary of an SEC filing — figures as filed
West Pharmaceutical Services WSTThe company said it appointed Robert McMahon as Senior Vice President & Chief Financial Officer, effective on August 4, 2025, and announced the appointment on July 21, 2025. He will oversee finance, audit, treasury, tax, investor relations and procurement.
Key points
AI summaryThe company said it appointed Robert McMahon as Senior Vice President & Chief Financial Officer, effective on August 4, 2025, and announced the appointment on July 21, 2025. He will oversee finance, audit, treasury, tax, investor relations and procurement.
The company said McMahon was most recently Chief Financial Officer of Agilent Technologies Inc. and served as Chief Financial Officer of Hologic, Inc. from 2014 to 2018. The company said Bernard Birkett is retiring and will serve as Senior Advisor to the CEO through December 31, 2025.
The company said McMahon's initial annual base salary is $800,000, and his annual incentive plan bonus target is 80% of base salary, prorated for his employment period in 2025. On August 11, 2025, he will receive a long-term incentive award with a grant date fair value of $3,000,000, consisting of 50% performance share units, 25% stock options and 25% restricted stock units.
The company said it will pay McMahon a one-time cash sign-on bonus of $3,115,000 and a one-time sign-on replacement equity grant with a grant date fair value of $4,200,000, consisting of restricted stock units of $3,000,000, stock options of $700,000 and performance share units of $500,000. The company said the awards are intended to partially compensate McMahon for incentives forfeited when he left his prior employer. It also said the cash bonus is subject to a 2-year repayment obligation.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Robert McMahon to become Senior Vice President & Chief Financial Officer on August 4
The company said it appointed Robert McMahon as Senior Vice President & Chief Financial Officer, effective on August 4, 2025, and announced the appointment on July 21, 2025. He will oversee finance, audit, treasury, tax, investor relations and procurement.
Source · Based on the filing body and exhibits
McMahon's prior roles and Bernard Birkett's successor role
The company said McMahon was most recently Chief Financial Officer of Agilent Technologies Inc. and served as Chief Financial Officer of Hologic, Inc. from 2014 to 2018. The company said Bernard Birkett is retiring and will serve as Senior Advisor to the CEO through December 31, 2025.
Source · Based on the filing body and exhibits
McMahon's base salary and annual and long-term incentive terms
The company said McMahon's initial annual base salary is $800,000, and his annual incentive plan bonus target is 80% of base salary, prorated for his employment period in 2025. On August 11, 2025, he will receive a long-term incentive award with a grant date fair value of $3,000,000, consisting of 50% performance share units, 25% stock options and 25% restricted stock units.
Source · Based on the filing body and exhibits
One-time sign-on bonus of $3,115,000 and replacement equity grant of $4,200,000
The company said it will pay McMahon a one-time cash sign-on bonus of $3,115,000 and a one-time sign-on replacement equity grant with a grant date fair value of $4,200,000, consisting of restricted stock units of $3,000,000, stock options of $700,000 and performance share units of $500,000. The company said the awards are intended to partially compensate McMahon for incentives forfeited when he left his prior employer. It also said the cash bonus is subject to a 2-year repayment obligation.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…